Conversely, a multivariable analysis including International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups (favorable, intermediate, or poor) found that low baseline HGF, GAS6, and VEGF were independently prognostic for improved OS with cabozantinib. This evidence concerns the gene VEGFA and renal cell carcinoma.